As of June 20, 2025, Biomea Fusion Inc (BMEA) reports a Gross Margin of 7775.20%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Comparing Biomea Fusion Inc's Gross Margin to Peers
To better understand Biomea Fusion Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Biomea Fusion Inc (BMEA) | 7775.20% |
| Neoimmunetech Inc (950220.KQ) | 7775.20% |
| Regeneron Pharmaceuticals Inc (REGN) | 87.01% |
| Vertex Pharmaceuticals Inc (VRTX) | 86.11% |
| Gilead Sciences Inc (GILD) | 78.26% |
| Biogen Inc (BIIB) | 77.18% |
Compared to its competitors, Biomea Fusion Inc's Gross Margin is higher than all peers, indicating superior product pricing power or cost efficiency in production.